S3 peptide

S3 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-MASGVAVSDGVIKVFNRQIKIWFQNRRMKWKK-OH

H-Met-Ala-Ser-Gly-Val-Ala-Val-Ser-Asp-Gly-Val-Ile-Lys-Val-Phe-Asn-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH

32

95.16%

C₁₇₄H₂₈₂N₅₂O₄₁S₂

3822.54

Synthetic

Powder

The S3 peptide includes the N-terminal 16 residues of human cofilin as well as a membrane-permeable peptide segment. S3 inhibits LIMK1-mediated cofilin phosphorylation in both HeLa and Cos-1 cells. Both HIV-1 and M-PMV particle outputs were significantly diminished by S3 treatment. Inhibiting LIMK1 kinase activity by S3 impairs both HIV-1 and M-PMV particle release.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Wen X, Ding L, Wang JJ, Qi M, Hammonds J, Chu H, Chen X, Hunter E, Spearman P. ROCK1 and LIM kinase modulate retrovirus particle release and cell-cell transmission events. J Virol. 2014 Jun;88(12):6906-21. doi: 10.1128/JVI.00023-14. Epub 2014 Apr 2. PMID: 24696479; PMCID: PMC4054354.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.